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1 Summary 
In felids, three hemotropic mycoplasma species (hemoplasmas) have been described: 
Mycoplasma haemofelis (Mhf), ‘Candidatus Mycoplasma haemominutum’ (CMhm), and 
‘Candidatus Mycoplasma turicensis’ (CMt). Particularly, Mhf may cause severe, 
potentially life-threatening hemolytic anemia. No routine serological assays for feline 
hemoplasma infections are available. Thus, the goal of this project was to identify an 
Mhf antigen (DnaK), to be used as a recombinant antigen in serological assays for the 
diagnosis of feline hemoplasma infections. The gene sequence of this protein was 
determined using consensus primers and blood samples from naturally and 
experimentally Mhf infected  cats, and a naturally  infected Iberian lynx (Lynx pardinus). 
Mhf DnaK was expressed recombinantly in an E. coli DnaK knock-out strain and purified 
using Ni-affinity, size exclusion, and anion exchange chromatography. It was then 
biochemically and functionally characterized and showed characteristics typical for 
DnaKs (secondary structure profile, thermal denaturation, ATPase activity, and DnaK 
complementation). Moreover, its immunogenicity was assessed using serum samples 
from experimentally hemoplasma infected cats. When the protein was applied in 
Western blot and enzyme-linked immunosorbent assays, it was recognized by sera from 
cats infected with Mhf, CMhm and CMt, respectively, but not from uninfected cats. This 
is the first description of a full-length purified recombinant feline hemoplasma antigen.
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2 Introduction 
Hemotropic mycoplasmas (hemoplasmas) are small (0.3 – 0.8 µm) epierythrocytic 
bacteria, which have previously been known as Haemobartonella and Eperythrozoon 
species. In felids, Mycoplasma haemofelis (Mhf), ‘Candidatus Mycoplasma 
haemominutum’ (CMhm) and ‘Candidatus Mycoplasma turicensis’ (CMt) have been 
described (5, 6, 19, 36). They vary in their pathogenicity, responsiveness to antimicrobial 
drugs, and probably in their ability to form a carrier state (5, 26, 36). Particularly Mhf may 
cause severe, potentially life-threatening hemolytic anemia (5). 
Real-time PCR assays are the tools of choice for diagnosing and differentiating feline 
hemoplasma infections (29, 36). However, they may not detect all hemoplasma 
infections, e.g. due to fluctuating Mhf bacteremia (29), reduced bacterial blood loads 
after antibiotic treatment (5), or chronic carrier status of infected animals with 
undetectable numbers of circulating hemoplasmas (28). To overcome the resulting 
diagnostic gap and to further characterize the course and pathogenesis of feline 
hemoplasma infections, a diagnostic assay based on serum antibody detection would be 
desirable. 
To date, no routine serological assays for the diagnosis of feline hemoplasma infections 
are available. The development of such assays has been significantly hampered by the 
fact that hemoplasmas cannot be cultured in vitro, and therefore antigens have had to 
be produced by experimental infection of cats with hemoplasmas. Experimental 
serological assays have been described using hemoplasma antigen either on blood 
smears (5) or purified from large volumes of blood (1) from infected cats. Western blot 
(WB) analyses of Haemobartonella felis antigen preparations resulted in the 
identification of five antigens recognized by sera from experimentally H. felis infected 
cats (1). A recent study identified Mhf antigens in crude antigen preparations from 
erythrocytes collected from an experimentally infected cat (21). Those antigens reacted 
with plasma antibodies of cats collected at different time points after experimental 
infection, when applied in WB analyses. The first recombinant hemoplasma antigen, 
Mycoplasma suis HspA1, was developed during a study in experimentally M. suis 
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infected pigs for the application in WB and enzyme-linked immunosorbent assays 
(ELISA) (10). This antigen belongs to the heat shock protein 70 (HSP70) family. It was 
found to be DnaK-like and present on the surface of M. suis (10). DnaKs are molecular 
chaperones consisting of an N-terminal nucleotide-binding domain (ATPase activity) 
which generates the energy necessary to refold misfolded proteins in cell stress 
situations (9). Misfolded proteins bind to the C-terminal substrate-binding domain of 
DnaKs. Most recently, we developed a recombinant feline hemoplasma antigen to 
demonstrate seroconversion of experimentally CMt infected cats in preliminary WB 
analyses (18). The antigen described was a truncated Mhf DnaK form, recombinantly 
expressed in E. coli, which was only partially purified leading to large inter-batch 
variations with regard to quality and purity. The described assay did not allow for 
quantification of antibody levels. 
The aim of this study was to identify the complete DnaK gene of Mhf, to recombinantly 
produce, highly purify and characterize the antigen, and to apply it in an ELISA as a 
quantitative serological tool for feline hemoplasma infection. 
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3 Materials and methods 
3.1 Animals, experimental hemoplasma infections, and samples 
For the present study, samples from the following six hemoplasma infected felids were 
used: the experimentally Mhf infected specified pathogen-free (SPF) cat QLA5 (Liberty 
Research; Waverly, NY/USA), the naturally Mhf infected Swiss domestic pet cats 1008 
and 7415 (35), the naturally Mhf infected free living Iberian lynx (Lynx pardinus) Dalia 
(16), the experimentally CMt infected SPF cat Y (18), and the experimentally CMhm and 
feline leukemia virus co-infected cat 09NFR2 (Liberty Research) ((7); 
www.vet.uzh.ch/dissertationen/index.php). In addition to samples from cats QLA5, 
09NFR2, and Y, pre and post hemoplasma infection samples from 17 SPF cats 
described earlier (7, 18) were used for the ELISA evaluation.  
For experimental Mhf infection, the SPF cat QLA5 was inoculated intraperitoneally at the 
age of 2.7 years with 2 ml of DMSO-preserved (20% v/v) Mhf positive blood 
(109 copies/ml) from the experimentally infected cat HF3 (31). The inoculum had been 
stored at -80°C until use. The experimental CMhm infection of the SPF cat 09NFR2 with 
a Spanish CMhm isolate derived from an Iberian lynx has been described previously (7). 
All SPF cats were kept in groups (QLA5 was kept together with a female neutered SPF 
companion cat), examined clinically prior to the study and their SPF status was verified 
as described previously (18).  
After hemoplasma inoculation, EDTA-anticoagulated whole blood samples were 
collected regularly, hemograms were generated using a Cell-Dyn 3500 (Abbott; 
Baar/Switzerland), and quantification of hemoplasma blood loads was performed by 
TaqMan real-time PCR (35). Serum or plasma samples were collected for serological 
analyses (see below). Anemia was defined as hematocrit value less than 33 % (equals 
5 % quantile of reference range determined in our laboratory using identical methods 
and blood samples from 58 clinically healthy cats). EDTA-anticoagulated blood samples 
collected from cat QLA5 10 days post infection (DPI; 4.4 x 108 copies/ml blood), cat 
1008 (2.8 x 108 copies/ml blood), cat 7415 (8.0 x 106 copies/ml blood), and from lynx 
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Dalia (6.6 x 104 copies/ml blood) were used for Mhf DnaK gene amplification and 
sequencing. DNA from 1 ml blood of cat QLA5 was extracted manually using the QIAmp 
DNA Blood Mini Kit (Qiagen; Hombrechtikon/Switzerland). Total nucleic acids from cats 
1008, 7415 and lynx Dalia were extracted from 200 µl of blood using the MagNa Pure 
LC Total Nucleic Acid Isolation Kit I (Roche Diagnostics; Reinach/Switzerland). 
3.2 Determination of Mhf DnaK gene sequence and phylogenetic analysis 
Based upon the sequence information of Mhf DnaK gene fragments AY150993 (303 bp) 
and FJ463263 (899 bp) and of all other mycoplasma DnaK gene sequences available 
from the GenBank database until June 2009, several consensus primer pairs were 
designed manually and tested for the amplification of the potential Mhf DnaK gene. 
Using the primer pairs F1-35Mp/R934-956Mhf and F600-623Var/R1746-1768Ms 
(Table 1), the Mhf DnaK gene was amplified as two overlapping fragments of 976 bp 
and 1,307 bp length, respectively. The following thermal cycling conditions were applied: 
initial denaturation at 98°C for 180 s, 35 cycles of 98°C for 10 s, 60°C (976 bp) or 63°C 
(1,307 bp) for 30 s, 72°C for 60 s, followed by final elongation at 72°C for 10 min. All 
DNA amplification steps of this study were performed using Phusion High-Fidelity DNA 
polymerase (Finnzymes; Espoo/Finland). The resulting PCR products of expected 
lengths were extracted from agarose gel using the NucleoSpin Extract II kit (Macherey-
Nagel; Düren/Germany) according to the manufacturer’s instructions. Gene sequences 
of the PCR products were determined by DNA sequencing (Microsynth; 
Balgach/Switzerland). Resulting Mhf DnaK gene and deduced protein sequences were 
compared to non-redundant nucleotide and amino acid database sequences using the 
BLASTN and BLASTP algorithms (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and were 
aligned to the mycoplasma DnaK sequences of species shown in Fig. 1 using ClustalW2 
(11). The phylogenetic tree of mycoplasma DnaK protein sequences was constructed 
using MEGA version 4 (27). Bootstrap support (1,000 replicates) was calculated by the 
neighbor-joining method. 
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3.3 Gene construction and molecular cloning 
The recombinant Mhf DnaK (Mhf rDnaK) gene was obtained in two steps: first, the Mhf 
DnaK gene was amplified as two overlapping fragments from DNA extracted from blood 
of cat QLA5 (primer pairs F1-35Mp/R934-956Mhf and F666-691Mhf/R1750-1783Mhf; 
Table 1). The resulting 976 bp and 1,119 bp long PCR products were extracted from 
agarose gel as described above and assembled in a second step, which combined 
10 ng of each of those fragments in an overlap extension PCR (50 µl reaction volume) 
using the overhang primers FDnaKMhfpET and RDnaKMhfpET (Table 1). Those primers 
also inserted NdeI- and XhoI-cleavage sites at the 5’- and 3’-ends of the gene, 
respectively. The following cycling conditions were used: 5 cycles with an annealing 
temperature of 85°C followed by the addition of primers and 35 cycles with an annealing 
temperature of 60°C (remaining cycling conditions as described above). The resulting 
PCR product (1,824 bp) was extracted from agarose gel, digested with restriction 
enzymes NdeI and XhoI (New England Biolabs; Ipswich, MA/USA) according to the 
manufacturer’s instructions and ligated to the 4,690 bp XhoI-NdeI fragment of vector 
pMG211 (24). The vector contained an ampicillin resistance gene, a salicylate-inducable 
promoter, and the genetic information for a C-terminal 6 x His tag followed by a stop 
codon. The correct Mhf rDnaK gene sequence within pMG211 was confirmed by DNA 
sequencing before protein production. For the DnaK complementation assay, the gene 
of E. coli chorismate mutase (EcCM; (12, 25)) was NdeI- and XhoI-digested and ligated 
to the XhoI-NdeI fragment of plasmid pMG211 as described above. 
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TABLE 1. Primers used for amplification and construction of the Mhf (r)DnaK gene 
Primer namea Sequence 5’ to 3’ Length (bp) 
Product 
length (bp) 
F1-35Mp GGCAAAAGAAATAATTTTAGGAATTGACTTAGG 33 
976 
R934-956Mhf CTTAACCAACTCCTGAACGGCAG 23 
F600-623Var GTGGTGACGATTGGGATCAAGC 22 
1,307 
R1746-1768Ms CTGATGCAGCTTGTCCTCCAGCA 23 
FDnaKMhfpET 
GCAGCACATATGGCAAAAGAAATAATTTTAGGAA
TTGACTTAGGb 
44 
1,824 
RDnaKMhfpET 
GCAGCACTCGAGGGATTTAGTTTTATCTACCTCA
GTCTTATCCTCc 
45 
F666-691Mhf GCACTTCAAAGACTTAAGGATGCCGC 26 
1,119 
R1750-1783Mhf TTAGGATTTAGTTTTATCTACCTCAGTCTTATCC 34 
 
a Primer names indicate forward (F) and reverse (R) orientation of the primers. All primers were used at a 
final concentration of 0.5 µM each. 
b Bold: NdeI recognition site. 
c Bold: XhoI recognition site. 
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3.4 Prokaryotic expression and purification of recombinant Mhf DnaK 
Plasmid pMG211, containing the Mhf rDnaK gene (naturally without UGA readthroughs), 
was transformed into the recA-deficient E. coli strain XL1 blue (Stratagene; LaJolla, 
CA/USA) for plasmid storage and multiplication. Cells were grown on LB agar containing 
150 µg/ml ampicillin and in LB medium containing 200 µg/ml ampicillin at 37°C and 250 
rpm, respectively. Plasmid DNA was purified using Jetquick Plasmid Miniprep Spin kit 
(Genomed; Löhne/Germany). Transformed XL1 blue cells were stored as glycerol stocks 
at -80°C. For protein production, plasmid pMG211 Mhf rDnaK was transformed into the 
kanamycin resistant strain JW0013, an in-frame DnaK knockout mutant of E. coli K-12 
(2). Preparative cultures were inoculated from overnight starter cultures and grown at 
30°C and 250 rpm in LB medium containing 150 µg/ml ampicillin and 25 µg/ml 
kanamycin. Gene overexpression was induced with 1 mM salicylate at OD600 of 0.6, and 
the culture was incubated for an additional 20 hours at 25°C and 250 rpm. After cell lysis 
using 1 mg/ml lysozyme and ultrasonication, protein was purified from the soluble 
fraction by affinity chromatography on Ni2+-NTA agarose (Qiagen). The purification 
progress was assessed by SDS-PAGE analysis (see below) after each purification step. 
Fractions containing monomeric Mhf rDnaK were isolated by size-exclusion 
chromatography on a calibrated Superdex 200 10/300 GL column (Amersham 
Pharmacia Biotech; Uppsala/Sweden) in TBS, pH 7.4. Those fractions were then 
subjected to anion exchange chromatography on a Mono Q HR 16/10 column 
(Amersham Pharmacia Biotech) in TBS, pH 7.4 using a salt gradient from 150 mM to 
500 mM NaCl. Fractions containing protein with a molecular mass of about 66 kDa were 
combined, concentrated using Amicon Ultra Centrifugal Filters 10 K (Millipore; 
Carrigtwohill, Cork/Ireland), and their protein concentration was determined by the 
Bradford assay (Coomassie Plus Protein Assay Reagent, calibrated with BSA; Thermo 
Scientific; Rockford, IL/USA). 
3.5 Molecular mass determination of recombinant Mhf DnaK 
The molecular mass of Mhf rDnaK protein was determined at the protein service unit of 
the Functional Genomics Center Zurich (FGCZ), University of Zurich, Switzerland. The 
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purified protein solution was analyzed using electrospray ionization mass spectrometry. 
The experimentally determined molecular mass was then compared to the mass 
calculated by the ProtParam tool (www.expasy.ch/tools/protparam.html) based on the 
deduced protein sequence of Mhf rDnaK. 
3.6 Structure and stability determination 
Circular dichroism (CD) spectroscopy was performed on an Aviv Circular Dichroism 
Spectrometer Model 202 (Aviv Instruments Inc; Lakewood, NJ/USA) in quartz cuvettes 
of 0.2 cm pathlength (d). Far-UV spectra were recorded from 260 to 200 nm in 1 nm 
steps at 25°C and 1 µM Mhf rDnaK protein concentration (c) in TBS, pH 7.4 (50 mM tris 
base, 150 mM NaCl). For stability studies, KCl (100 mM) together with MgCl2 (2.5 mM) 
and/or ATP (0.1 mM) were added. Data were collected for 5 s at each step. Five scans 
were averaged and buffer spectra determined under identical conditions were 
subtracted. The observed ellipticity (θλ) at wavelength λ was transformed into molar 
ellipticity per residue (θm,r) using equation 1 (where n is the number of residues). 
(1)  ߠ௠,௥  ൌ ఏഊଵ଴·௖·ௗ·௡ 
Thermal denaturation experiments were performed in TBS, pH 7.4, at 1 µM protein 
concentration by monitoring the CD signal at 222 nm from 10°C to 95°C and reverse in 
0.5 K steps with 60 s temperature equilibration, 60 s data collection, and 1 K per minute 
heating/cooling rate between temperature steps. Tm, the melting point of the Mhf rDnaK 
ATPase domain, was defined as the inflection point of the melting curve and was 
determined from the first derivative after curve smoothing using the SigmaPlot v11.0 
software package (Systat Software Inc; Richmond, CA/USA). 
3.7 ATPase activity assay 
ATPase activity was measured using a spectrophotometric assay (32), which quantified 
the released amount of inorganic phosphate (Pi) during ATP hydrolysis. The reaction of 
2-amino-6-mercapto-7-methylpurine-ribonucleoside (MESG) with Pi was catalyzed by 
the purine nucleoside phosphorylase (PNP; Sigma-Aldrich; Buchs/Switzerland) and led 
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to a measurable change in absorbance at 360 nm. MESG was synthesized and purified 
as previously published (32). All measurements were performed at 25°C and 1 U/ml 
PNP. The change in absorbance at 360 nm was calibrated to the Pi concentration using 
MESG (190 µM) and Pi (0, 1, 5, 25, and 50 µM; from 200 µM Na2HPO4-solution). 
Michaelis-Menten kinetic measurements of Mhf rDnaK where then performed under the 
following ATPase assay conditions: 50 mM Tris, 100 mM KCl, 2.5 mM MgCl2, 400 nM 
purified Mhf rDnaK, and 380 µM MESG. The change in absorbance at 360 nm was 
measured in duplicates for 26 min at ATP concentrations of 10, 50, 100, 250, and 
500 µM after an equilibration time of 4 min in a Lambda 35 spectrophotometer 
(PerkinElmer; Waltham, MA/USA). Blank values measured without Mhf rDnaK were 
subtracted and the reaction rates were calculated. The catalytic parameters kcat and Km 
were determined from curve fitting to the Michaelis-Menten equation using the 
SigmaPlot v11.0 software package (Systat Software Inc). 
3.8 DnaK complementation assay 
The E. coli DnaK knock-out mutant strain JW0013 was transformed with plasmid 
pMG211 containing either the Mhf rDnaK or the EcCM gene (as negative control). Liquid 
cultures were prepared from both transformants and incubated at 30°C and 250 rpm 
overnight. Cell densities of both cultures were adjusted to OD600 of 3.0 and cultures were 
then diluted sequentially tenfold down to 10-6. One 5 µl drop of each culture and dilution 
was placed on LB agar plates containing 150 µg/ml ampicillin, 25 µg/ml kanamycin and 
1 mM salicylate. Agar plates were incubated without ventilation at 30°C or 43°C, 
respectively. Bacterial growth was assessed after 22.5 hours by counting colonies. 
3.9 SDS-PAGE and recombinant antigen-based Western blot 
SDS-PAGE and protein transfer to nitrocellulose membranes were performed in a 
PhastSystem High Speed Electrophoresis System, a PhastSystem development unit, 
and a PhastTransfer semi-dry electrophoretic blotting unit (all Amersham Pharmacia 
Biotech). Recombinant Mhf DnaK (540 ng/lane) was separated on PhastGel 20 % (w/v) 
homogenous SDS polyacrylamide gels (Amersham Pharmacia Biotech), transferred, 
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and Coomassie-stained according to the manufacturer’s instructions. WBs were probed 
with pre and post infection serum or plasma samples from the experimentally infected 
cats QLA5 (Mhf; prior to and 21 DPI), 09NFR2 (CMhm; prior to and 56 DPI), and Y 
(CMt; prior to and 109 DPI). Serum and plasma samples were diluted 1:100 in blocking 
buffer (150 mM NaCl, 10 mM tris base, 20 g/l skimmed milk powder). Serum antibodies 
bound to Mhf rDnaK were visualized using peroxidase-conjugated, affinity-purified goat 
anti-cat IgG antibodies (diluted 1:2,000 in blocking buffer; Jackson ImmunoResearch 
Laboratories; West Grove, PA/USA) and 4-chloro-1-napthtol as the chromogenic agent.  
3.10 Recombinant antigen-based ELISA 
Mhf rDnaK was heated in coating buffer (100 mM Na2CO3, 0.1 % (w/v) SDS, pH 9.6) to 
100°C for one minute and then diluted 1:20 in coating buffer without SDS. Flat-bottomed 
96-well microtiter plates with medium binding capacity (Greiner Bio-One; 
Frickenhausen/Germany) were then coated with 100 µl/well of this Mhf rDnaK solution 
for three hours at 37°C and overnight at 4°C. Plates were subsequently washed three 
times with 200 µl/well washing buffer (150 mM NaCl, 0.05 % (v/v) Tween 20) and 
incubated for 1 hour at 37°C with 100 µl/well blocking buffer (150 mM NaCl, 50 mM tris 
base, 1 mM Titriplex III, 0.1 % (w/v) bovine serum albumin (BSA), 0.1 % (v/v) Tween 20, 
pH 7.4). After washing as described above, 100 µl of serum samples diluted in serum 
buffer (blocking buffer without BSA) were added per well and incubated for 1 hour at 
37°C. The plates were washed, each well was then filled with 100 µl of peroxidase-
conjugated, affinity-purified goat anti-cat IgG antibodies (diluted 1:3,000 in serum buffer; 
Jackson ImmunoResearch Laboratories) and incubated for 1 hour at 37°C. After 
washing, 100 µl/well substrate solution (150 mM citric acid pH 4.0, 1 % (v/v) H2O2 2 %, 
1 % (v/v) 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt) were 
added and plates were incubated at room temperature for 10 minutes. Absorbance was 
then measured at a wavelength of 415 nm using a Spectramax Plus 348 microplate 
spectrophotometer (Molecular Devices; Sunnyvale, CA/USA).  
Optimal serum dilutions and recombinant antigen concentrations were established by a 
checkerboard titration using pre and post infection sera from the three experimentally 
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infected cats QLA5 (Mhf; prior to and 21 DPI), 09NFR2C (CMhm; prior to and 56 DPI), 
and Y (CMt; prior to and 109 DPI) at serum dilutions of 1:50, 1:100, and 1:200. Antigen 
amounts of 200, 100, 50, and 10 ng/well were tested in duplicates. Wells containing only 
antigen without serum served as blanks, wells containing pre infection serum samples 
served as negative controls.  
Serum samples from 20 hemoplasma free SPF cats before and after hemoplasma 
infection were tested using optimized conditions. For cat QLA5, samples taken during 
the whole course of experimental Mhf infection (0 to 800 DPI), were assayed 
additionally. 
3.11 Statistical analyses 
Statistical analyses were performed using the SigmaPlot v11.0 software package (Systat 
Software Inc). Correlations between ELISA antibody levels and Mhf blood loads in the 
experimentally Mhf infected cat QLA5 were assessed using the Spearman rank order 
correlation test. 
3.12 GenBank accession numbers 
The nucleotide and deduced amino acid sequences of Mhf DnaK have been deposited 
in the GenBank database (HM594280, HM594281, HM594283). Additionally, a partial 
CMhm DnaK sequence, acquired using identical methods, was submitted (HM594282). 
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4 Results 
4.1 Mhf DnaK sequences 
The obtained sequences of the potential Mhf DnaK gene included, according to BLASTN 
search results, an open reading frame (ORF) most similar to mycoplasma DnaK gene 
sequences (data not shown). When compared to mycoplasma DnaK complete gene 
sequences from the GenBank database, the highest identities with this ORF were found 
for M. suis DnaK (HspA1; 72 %) and Mycoplasma penetrans DnaK (69 %). Identities 
with the two partial Mhf DnaK gene sequences FJ463263 (899 bp) and AY150993 
(303 bp) were 99 % and 97 %, respectively. Accordingly, the ORF was named Mhf 
DnaK gene. Further comparisons of Mhf DnaK gene sequences derived from four 
different Mhf infected animals resulted in three distinct Mhf DnaK gene sequences: from 
cats 7415 and QLA5 an identical sequence was obtained (HM594280). Sequences 
obtained from cat 1008 (HM594283) and lynx Dalia (HM594281) shared the same 21 
silent point mutations as well as one point mutation causing a serine to glycine 
exchange at position 580, when compared to the 7415/QLA5 sequence. The sequence 
from lynx Dalia (HM594281) additionally contained a point mutation causing a proline to 
serine exchange at position 577. When the deduced Mhf DnaK protein sequence (cats 
7415/QLA5; HM594280) was compared to mycoplasma DnaK sequences from the 
GenBank database using the BLASTP search algorithm, again M. suis (70 %) and M. 
penetrans (65 %) shared highest identities. Phylogenetic analyses of the Mhf DnaK 
protein sequence revealed it to cluster within the haemofelis group of the hemoplasmas, 
distinct from other mycoplasma groups (Fig. 1). 
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4.2 Expression and biochemical characterization of recombinant Mhf DnaK 
Ni-affinity chromatography of crude extracts of salicylate-induced JW0013 pMG211 Mhf 
rDnaK cells yielded one predominant protein band corresponding to a molecular mass of 
about 66 kDa (data not shown). After size exclusion, anion exchange chromatography, 
and protein concentration, Mhf rDnaK was judged to be pure by SDS-PAGE (Fig. 3A). 
Mass spectrometry analysis determined the molecular mass of Mhf DnaK to be 
66,406 Da, whilst the calculated molecular mass based on its deduced protein sequence 
was 66,537 Da. This difference in mass of 131 Da corresponds to the N-terminal loss of 
methionine during mass spectrometry analysis. 
CD spectrum analysis of Mhf rDnaK showed two distinct minima at 208 and 222 nm 
(Fig. 2A). The CD spectrum of Mhf rDnaK recorded without ATP or K+ and Mg2+ ions 
was not markedly different from those recorded with additives. The temperature-
dependent CD signals at 222 nm showed thermally induced unfolding of Mhf rDnaK with 
well-defined (Tm1) and less well-defined (Tm2) temperature transitions (Fig. 2B). The 
melting temperature of the nucleotide-binding domain of Mhf rDnaK without additives 
was determined as Tm1a of 42°C, addition of the nucleotide ATP increased it to Tm1c of 
46°C and ATP together with K+ and Mg2+ ions further increased it to Tm1d of 50°C. 
Addition of K+ and Mg2+ ions alone only caused a minimal increase to Tm1b of 43°C.  
Enzymatic activity of the ATPase domain of Mhf rDnaK was determined in a 
spectrophotometric assay. Fitting reaction rates at varying substrate concentrations to 
the Michaelis-Menten equation, yielded catalytic parameters for ATP hydrolysis 
(Fig. 2C). 
During the DnaK complementation assay, the in vivo biological function of DnaKs to 
allow bacterial growth at cell-stressing temperatures, was tested for Mhf rDnaK. No 
difference in the extent of bacterial growth between the Mhf rDnaK and the EcCM 
transformant could be seen for any of the tested culture dilutions at 30°C (Fig. 2D). At 
43°C, however, cells overexpressing EcCM and lacking DnaK protein only grew until a 
dilution of 10-1 (20 colonies), while for rDnaK expressing cells growth until a 10-3 dilution 
(1 colony) was observed (Fig. 2D). 
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FIG. 2. Biochemical and functional characterization of Mhf rDnaK. (A) Circular dichroism 
spectra of Mhf rDnaK in the absence or presence of ATP and/or K+ and Mg2+ ions. (B) 
Thermal denaturation curves of Mhf rDnaK recorded at a wavelength of 222 nm in the 
absence or presence of ATP and/or K+ and Mg2+ ions. T, temperature (C) Michaelis-
Menten plot of Mhf rDnaK (400 nM) showing ATPase activity at indicated ATP 
concentrations. The kinetic constants kcat and Km of Mhf rDnaK were determined from 
curve fitting to the Michaelis-Menten equation. (D) Evaluation of in vivo complementation 
of biological DnaK function by Mhf rDnaK in the DnaK-deficient E. coli strain JW0013 at 
permissive (30°C; upper panel) and non-permissive (43°C; lower panel) temperatures. 
JW0013 cells were either expressing the Mhf rDnaK gene (Mhf rDnaK) or the E. coli 
chorismate mutase gene (EcCM), the latter serving as negative control. Overnight 
cultures of transformed cells were diluted sequentially tenfold down to 10-6 before being 
spotted onto selective agar plates supplemented with 1 mM salicylate. Their ability to 
grow was evaluated by counting colonies. 
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4.3 Immunogenicity of the recombinant Mhf DnaK 
WB analyses of Mhf rDnaK showed that the protein was recognized by serum antibodies 
from cats experimentally infected with Mhf (cat QLA5), CMhm (cat 09NFR2), and CMt 
(cat Y). Pre infection serum or plasma samples from the same cats did not result in a 
positive WB signal (Fig. 3B). 
For the Mhf rDnaK ELISA, 50 ng Mhf rDnaK/well and a dilution of 1:200 for sera from 
Mhf infected cats and 1:100 for sera from CMhm and CMt infected cats were found to be 
the optimal conditions. OD415 values for serum samples from 20 SPF cats prior to 
hemoplasma infection ranged from 0.12 to 0.33 under these conditions. The ELISA 
signal ratio (OD415 value post/pre infection) of the Mhf, CMhm and CMt infected SPF 
cats reached a maximum of 10.4, 10.4 and 10.6, respectively. An ELISA signal ratio of 
at least 1.5 was considered serologically positive for anti-Mhf rDnaK antibodies. 
 
 
 
FIG. 3. (A) SDS-PAGE of recombinant Mhf DnaK for purity assessment after the final 
purification step of anion exchange chromatography. M, low molecular weight marker 
(Amersham Pharmacia Biotech); 1, Mhf rDnaK (B) Western blot analyses of pre and 
post feline hemoplasma infection samples using  540 ng recombinant Mhf DnaK per 
lane. Blots were reacted with serum from Mhf infected cat QLA5 prior to (lane 2) and 21 
DPI (lane 3), plasma from CMhm infected cat 09NFR2 prior to (lane 4) and 56 DPI (lane 
5), and serum from CMt infected cat Y prior to (lane 6) and 109 DPI (lane 7). M, peqGold 
prestained protein marker IV (PEQLAB Biotechnologie; Erlangen, Germany) 
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4.4 Experimental Mhf infection and quantification of anti-Mhf DnaK 
antibodies 
The experimentally Mhf infected cat QLA5 turned Mhf TaqMan real-time PCR-positive 
within 4 DPI and became anemic within 10 DPI (Fig. 4A). On the day of infection (0 DPI) 
the cat was mildly anemic (hematocrit of 28 %), probably due to a baseline blood 
collection of 26 ml eleven days prior to Mhf infection. However, the cat recovered to 
hematocrit values within the reference range within a few days (7 to 9 DPI) before a 
decrease in the hematocrit was observed starting 10 DPI. The minimum hematocrit 
value of 15 % was measured 36 DPI (Fig. 4A). However, no severe clinical signs were 
observed that necessitated blood transfusion or antibiotic treatment during the course of 
infection and the cat subsequently recovered from anemia. From 148 DPI (5.3 months 
post infection, MPI) onwards, the hematocrit values stayed within the reference range 
until the end of the experiment, 28.6 MPI (Fig. 4A and data not shown).  
The peak Mhf load in blood (2.2 x 108 copies/ml blood) was recorded at 29 DPI. 
Between 4 and 42 DPI the first marked Mhf copy number fluctuations were observed; 
they ranged from 103 to 108 Mhf copies/ml blood within a minimum of two days (Fig. 4A). 
From 3.8 to 8.3 months post infection (MPI) a second episode of copy number cycling 
was observed; the loads ranged from 102 to 105 copies/ml blood within a minimum of 
eight days. Five distinct Mhf load peaks were observed in one to two month intervals 
during this second cycling period. QLA5 stayed PCR-negative from 260 DPI (9.3 MPI) 
until the end of the observation period at 28.6 MPI (Fig. 4A and B).  
Seroconversion of cat QLA5, defined as an ELISA signal ratio of at least 1.5, occurred 
between 8 (signal ratio 1.3) and 14 DPI (signal ratio of 6.9; Fig. 4B). QLA5 stayed 
serologically positive until the end of the observation period at 28.6 MPI. Twelve and 
eighteen MPI the ELISA signal ratio dropped to minima of 2.8, followed by a signal ratio 
increase to 6.0 without detectable amounts of Mhf DNA in the cat’s blood (Fig. 4B). 
Reinfection of QLA5 by its SPF companion cat as cause for this ratio increase was 
excluded by negative PCR and serology results for the companion cat before, during, 
and at the end of the observed infection period (data not shown).  
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There was a significant positive correlation between the ELISA signal ratio and Mhf load 
when all pairs of variants throughout the whole course of infection (n = 32) were 
included (Spearmen correlation coefficient r = 0.619; p = 0.0002) as well as when only 
pairs of variants from the PCR-positive period (n = 21, r = 0.502, p = 0.0202) were 
included. 
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FIG. 4. Course of experimental Mhf infection in cat QLA5: hematocrit, Mhf load, and anti-
Mhf rDnaK antibodies. (A) Hematocrit and Mhf blood copy numbers during the first year 
of experimental Mhf infection. Mhf blood copy numbers were determined using TaqMan 
real-time PCR (35). The dashed lines indicate the lower and the upper limit (5 % and 
95 % quantiles) of the hematocrit reference range (33 % to 45 %). (B) Anti-Mhf rDnaK 
serum antibodies and Mhf blood copy numbers during 29 months of experimental Mhf 
infection. 
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5 Discussion 
This is the first study to identify, characterize, and recombinantly produce a full-length, 
highly pure antigen of feline hemotropic mycoplasmas. The protein is a HSP70 and 
belongs to the DnaK protein family. It is most closely related to HspA1, the DnaK of 
M. suis (CAK22359); the latter protein was demonstrated to be expressed on the surface 
of M. suis cells and to have immunogenic potential (10). In analogy to this, we found that 
hemoplasma infected cats readily produced antibodies to Mhf rDnaK.  
The protein crossreacted with sera from cats experimentally infected with Mhf, CMhm 
and CMt, but not with serum samples from SPF cats. However, optimization of the 
ELISA resulted in higher sample dilutions for Mhf samples than for CMhm and CMt 
samples, which possibly indicates that the immunogenicity of Mhf rDnaK is caused by 
conserved as well as species-specific epitopes of this antigen. This would on the one 
hand be in agreement with the high identity (71 %) that we found between the Mhf DnaK 
and the partial CMhm DnaK gene sequence (1,304 bp; HM594282) but could also 
explain why we were unable to amplify the 3’-end of the CMhm DnaK gene sequence 
using consensus primers despite several attempts (data not shown). The observed 
crossreactivity is also in agreement with a previous study using whole feline 
hemoplasma antigen preparations (5). In the latter study, antigen derived from H. felis 
large form (today known as Mhf) was tested with sera from cats infected with Mhf and 
CMhm (formerly known as H. felis small form). Mhf-derived whole hemoplasma antigen 
crossreacted with sera from Mhf and CMhm infected cats, while CMhm-derived antigen 
was only recognized by sera from CMhm infected cats. 
The antigen Mhf rDnaK was purified to homogeneity from potentially antigenic proteins 
originating from the production process to improve the signal quality of the serological 
assays and to minimize inter-batch variations in antigen quality. Indeed, Mhf rDnaK 
protein expression and purification was repeated with identical results. The identity of 
the protein was proven by the comparison of the observed and calculated molecular 
masses of Mhf rDnaK. CD spectrum analysis of Mhf rDnaK revealed two minima (at 
208 nm and 222 nm) suggesting that it consisted mostly of α-helices (8), which is in 
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good agreement with known DnaK structures e.g., of E. coli (PDB ID: 2KH0) and G. 
kaustophilus (PDB ID: 2V7Y). The structure profile of Mhf rDnaK was insensitive to 
change in the presence of nucleotide as has been shown before for 
Bacillus licheniformis DnaK (13) and also in the presence of K+ and Mg2+ ions. Thermal 
denaturation of Mhf rDnaK was characterized by two temperature transitions. This 
corresponded well to an earlier study (17), where deletion mutants of E. coli DnaK were 
used. The authors demonstrated that the first transition (Tm1) was related to the 
unfolding of the DnaK N-terminal nucleotide-binding domain, while the second transition 
was related to the unfolding of the C-terminal substrate-binding domain. A raising of Tm1 
in the presence of nucleotide, as also observed for Mhf rDnaK, was reported for E. coli 
DnaK to be caused by a stabilizing effect occurring due to the ligand binding to the 
nucleotide-binding domain of the protein (20). As found for Mhf rDnaK, this stability was 
supposed to be further enhanced in the presence of nucleotide together with K+ and 
Mg2+ ions, which mediate contacts between DnaK and nucleotide (15, 33). The kinetic 
constants for ATP hydrolysis by pure Mhf rDnaK (kcat = 0.015/min, Km = 23 µM, 
kcat/Km = 650/M/min; Fig. 2C) were comparable to those published for E. coli DnaK: kcat 
values ranging from 0.02 to 0.2/min (3) and Km values ranging from 20 nM to 20 µM (4, 
14). This indicated that Mhf rDnaK possesses a typically low ATPase activity when 
evaluated without its cochaperones DnaJ and grPE. The DnaK complementation assay 
confirmed the molecular chaperone activity of Mhf rDnaK in an E. coli DnaK knock-out 
mutant at heat shock temperatures. 
We demonstrated for the first time that an experimentally Mhf infected cat mounted 
antibodies to Mhf rDnaK within 8 to 14 days after experimental infection and shortly after 
the cat had turned Mhf PCR-positive in the blood. Moreover, we found a correlation 
between the Mhf blood loads and antibody levels. This indicates that the Mhf DnaK is 
immunogenic and that the recombinant antigen is suited for use in quantitative 
serological assays and to demonstrate seroconversion in infected animals.  
The experimentally Mhf infected cat stayed serologically positive for more than two 
years post infection and for more than one and a half years after turning PCR-negative 
for Mhf in the blood. So far, we have data from only Mhf infected cat. However, earlier 
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results from CMt infection (18) and preliminary follow-up data from these cats (Novacco 
et al.; in preparation) confirm the persistence of anti-Mhf rDnaK antibodies in the 
absence of PCR-positivity in blood. This might indicate that there is active antigen 
stimulation in the chronic phase of hemoplasma infection possibly by antigen 
sequestered in the tissue. We have postulated that the decline of WB signal in two cats 
after antibiotic treatment of experimental CMt infection could have been due to therapy-
induced CMt clearance from blood and tissues (18), whereas CMt antigen sequestered 
in the tissues of ten untreated cats could have resulted in the continuous low-level 
stimulation of the humoral immune system (18). This latter would be in agreement with 
the findings from two experimentally CMt infected cats: in nearly all tissues collected 
from those two cats at 20 and 94 DPI, respectively, more CMt copies were found than 
expected to result from blood contamination alone, which suggested that CMt might well 
become concentrated in organs of infected cats (personal communication S. Tasker). 
However, for Mhf no evidence for significant tissue sequestration has been found so far 
(30). 
 In conclusion, this study provides evidence that Mhf rDnaK, the antigen we have 
identified, recombinantly produced, and characterized herein, has biochemical and 
molecular chaperone properties of the HSP70/DnaK family. It has been applied 
successfully to quantify anti-feline hemoplasma antibodies in samples from 
experimentally infected cats, as well as to monitor seroconversion after infection when 
used in WB assays and ELISA. The antigen and the assays are prerequisites to gain 
more insight into the course of hemoplasma infections, e.g. by investigating 
hemoplasma pathogenesis in experimental infection setups. In addition, the described 
antigen may have the potential to be used in a rapid test for clinicians, supporting quick 
diagnosis and faster choice of adequate therapy of feline hemolytic anemia. However, 
further studies will be necessary to fully evaluate the crossreactivity of this antigen with 
antibodies directed against other bacterial pathogens and its potential benefit for testing 
samples from naturally hemoplasma infected cats. 
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